Work

Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.tps4591

Authors: Ashish M. Kamat, Neal D. Shore, Noah M. Hahn, Shaheen Riadh Alanee, Hiroyuki Nishiyama, Shahrokh F. Shariat, Kijoeng Nam, Ekta Kapadia, Tara L. Frenkl, Gary D. Steinberg

Institutions: The University of Texas MD Anderson Cancer Center, Carolina Urologic Research Center, Johns Hopkins University, Henry Ford Hospital, University of Tsukuba, Medical University of Vienna, Merck & Co., Inc., Rahway, NJ, USA (United States), University of Chicago Medical Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947275031

Cites:

Cited by: 4

Related to: 10